Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | FIS | Stock Option (Right to Buy) | Award | $2.94M | +40.4K | $72.88 | 40.4K | Feb 28, 2023 | Common Stock | 40.4K | $72.88 | Direct | F1, F2 | |
transaction | FIS | Stock Option (Right to Buy) | Award | $3.57M | +45.1K | $79.21 | 45.1K | Feb 28, 2023 | Common Stock | 45.1K | $79.21 | Direct | F1, F2 | |
transaction | FIS | Stock Option (Right to Buy) | Award | $3.92M | +47.6K | $82.38 | 47.6K | Feb 28, 2023 | Common Stock | 47.6K | $82.38 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | In a Form 4 filed on March 2, 2023, the reporting person reported receipt of a grant of premium stock options on February 28, 2023 that would vest and become exercisable over three years with a different premium exercise price for each vested tranche. These options should have been reported as three separate grants (rather than one consolidated grant in the same aggregate amount), with 15%, 25%, and 30% premium exercise prices to the closing price on February 28, 2023 of $63.37, and each vesting and becoming exercisable in three equal installments over three years. There were no additional grants of premium stock options made to reporting person in fiscal 2023. |
F2 | The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date. |